Buy These Stocks If You Want 126% to 206% Returns, Says Wall Street

Shares of clinical-stage biotech companies can skyrocket in a short period based on positive clinical and regulatory news. That's why investors looking for explosive gains often turn to this exciting industry to find worthwhile investments.

Of course, it's essential to consider the risks involved before investing, too. With that said, let's look at two clinical-stage biotechs that currently boast significant upside potential if we go by average price targets assigned by Wall Street analysts: CRISPR Therapeutics (NASDAQ: CRSP) and Axsome Therapeutics (NASDAQ: AXSM).

Continue reading

Source Fool.com